|
May 9, 2022
|
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022 , expected to fund current operating plan into the fourth quarter of 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion
|
|
May 3, 2022
|
Sesen Bio Provides Strategic Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of
|
|
Feb 28, 2022
|
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
Participated in productive CMC and Clinical Type A Meetings with the FDA in the fourth quarter Type C Meeting with the FDA planned for March 28, 2022 Strong balance sheet with $163M in cash and cash equivalents as of December 31, 2021 expected to fund current operating plan into 2024 CAMBRIDGE,
|
|
Jan 10, 2022
|
Sesen Bio Further Enhances Team with Key Hires
Minori Rosales , M.D., Ph.D. Brings Over 15 Years of Clinical Experience Stephanie Vigue to Support Company’s Mission with Broad Corporate Finance Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2022-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein
|
